# NCT05806515 (NCT05806515)

> Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation

No report yet. It can be ordered.

- Drugs tested: carboplatin
- Indication: localized high-risk prostate cancer with germline BRCA1/2 mutations

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05806515
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: SWOG Cancer Research Network
- Conditions: Prostate Adenocarcinoma; Stage IIIB Prostate Cancer AJCC v8; Stage IIIC Prostate Cancer AJCC v8
- Interventions: Biospecimen Collection; Carboplatin; Chest Radiography; Computed Tomography; Magnetic Resonance Imaging; PSMA PET Scan; Surgical Procedure
- Enrollment: 44
- Primary outcome: Pathologic complete response after neoadjuvant carboplatin

## Indexed commentary on NCT05806515 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 5 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct05806515